BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 15667617)

  • 1. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
    Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil without antibody induction in cadaver vs. living donor pediatric renal transplantation.
    Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; Hasan SM; Concepcion W
    Pediatr Transplant; 2003 Apr; 7(2):137-41. PubMed ID: 12654055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basiliximab induction in renal transplantation: long-term outcome.
    Atlani M; Sharma RK; Gupta A
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
    Gentile G; Somma C; Gennarini A; Mastroluca D; Rota G; Lacanna F; Locatelli B; Remuzzi G; Ruggenenti P
    Am J Nephrol; 2015; 41(1):16-27. PubMed ID: 25612603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
    Hesse UJ; Troisi R; Jacobs B; Van Vlem B; de Hemptinne B; Van Holder R; Vermassen F; De Roose J; Lameire N
    Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.
    Neu AM; Ho PL; Fine RN; Furth SL; Fivush BA
    Pediatr Transplant; 2003 Jun; 7(3):217-22. PubMed ID: 12756047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression.
    Gavela Martínez E; Avila Bernabeu AI; Sancho Calabuig A; Beltrán Catalán S; Escudero Quesada V; Pallardó Mateu LM
    Transplant Proc; 2009; 41(6):2337-8. PubMed ID: 19715913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?
    Jorge S; Guerra J; Silva S; Santana A; Mil-Homens C; Prata MM
    Transplant Proc; 2008 Apr; 40(3):693-6. PubMed ID: 18454989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
    Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of kidney transplantation in patients receiving MMF- or MMF and basiliximab-containing immunosuppression.
    Tojimbara T; Nakajima I; Sato S; Nakamura M; Kawase T; Kai K; Tsuda S; Kudo S; Fuchinoue S; Teraoka S
    Transplant Proc; 2004 Sep; 36(7):2087-9. PubMed ID: 15518755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes.
    Humar A; Crotteau S; Gruessner A; Kandaswamy R; Gruessner R; Payne W; Lake J
    Clin Transplant; 2007; 21(4):526-31. PubMed ID: 17645714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction with basiliximab in renal transplantation.
    Ferrer F; Machado S; Alves R; Macário F; Bastos C; Roseiro A; Mota A
    Transplant Proc; 2010 Mar; 42(2):467-70. PubMed ID: 20304166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
    Tojimbara T; Sato S; Koyama I; Nanmoku K; Sekijima M; Tonsyo M; Kai K; Kato Y; Urashima Y; Nakajima I; Fuchinoue S; Teraoka S
    Transplant Proc; 2005 Mar; 37(2):895-8. PubMed ID: 15848568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.